Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-stratified therapy for pediatric de novo AML
NCT02848183Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jan 2016
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, idarubicin, mitoxantrone, etoposide in acute myeloid leukemia (AML), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
cytarabineidarubicinmitoxantroneetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02848183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848183.